Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/21/2012 | 02:16am CEST

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

XIANYANG, China, April 20, 2012/PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in Chinafor a variety of diseases and conditions, today announced that it has received written notification from the Nasdaq Listing Qualifications department that it has regained compliance with the minimum bid price requirement of $1.00per share for continued listing of its common stock on The NASDAQ Global Market set forth in Nasdaq Listing Rule 5450(a)(1), as its common shares achieved a closing bid price of $1.00or more for 10 consecutive business days prior to the compliance deadline of April 23, 2012and this matter is now closed.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to maintain its ongoing compliance with the Nasdaq continued listing requirements, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




BioStar Pharmaceuticals, Inc. 

The Equity Group, Inc.

Zack Pan, CFO 

Lena Cati

Tel: 405-996-8829 

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
02:18a DEUTSCHE BANK : to expand Irish workforce
02:17aDJGREATER NEW YORK WATCH : Three Wounded in Newark Street Shooting
02:14a SHUI ON LAND : Proposed notes issue to be guaranteed by the company
02:14a INCREMENTAL OIL AND GAS : Canary Networks Investor Forum Presentation
02:13a CHEMTURA : To Be Acquired By LANXESS In $2.5 Bln Deal
02:11a MACY : The Sacramento Bee Tony Bizjak column
02:10a HUAWEI CULTURE : Leica Camera AG, Huawei establish new R&D center
02:09a Custom protection for Chinese
02:09a Banks fight back in the consumer finance market
02:07a Majority of UK CEOs considering moving operations abroad post-Brexit - survey
Latest news
Advertisement
Hot News 
21.42%Twitter In Talks with Suitors, Including Salesforce, Google -CNBC's Faber
15.45%Endo International CEO steps down, Campanelli named successor
9.77%SANTANDER CONSUMER : USA to Restate Financial Reports
-5.17%FINISH LINE : Comparable Store Sales Rise
-3.52%AP MOELLER MAERSK A/S : A.P. Moeller-Maersk to Split Into Two Separate Divisions -- 4th Update
Most Read News
06:51p COOPERATIVE CONSTRUCTION : Ansamed news service
07:03p MARMOTA ENERGY : Change In Directors Interest Notice
06:25p DGAP-ADHOC : LANXESS signs contract to acquire Chemtura
07:14p CARPENTARIA EXPLORATION : Emirates Steel signs LOI for Hawsons DR pellets
06:09p VEOLIA ENVIRONNEMENT : France's CDC planning multiple stake sales - FT
Most recommended articles
06:09p VEOLIA ENVIRONNEMENT : France's CDC planning multiple stake sales - FT
06:07p HERE, automakers team up to share data on traffic conditions
05:53pDJTWITTER : Salesforce Weighs Twitter Bid to Spur Growth
05:08pDJFORD MOTOR : Car Makers Maneuver Europe's Turns
04:38pDJANHEUSER BUSCH INTERBREW : MillerCoors Attacks Bud Light in New Ad Campaign